Therefore, epigenetic treatment (HDAC inhibitors) can constrain breast cancer cell growth, in part, via activation of the Nrf2-dependent antioxidant pathways, mediated by the re-expression of miR-200a and the targeting of the Keap1 3’-UTR. This evidence concerns the gene KEAP1 and breast carcinoma.